
Sunday, August 20, 2023 12:24:51 PM
But because of the age of Linda and Les -- around 70 in average, they can do only that so it's no surprise to see delay, delay and delay, of course a significant part of that is due to the complex nature of seeking approvals of DCVax-L by multiple RAs from a trial which is unprecedented in many ways. Nonetheless it will be definitely approved by the multiple RAs due to its results are "both statistically significant and clinically meaningful" -- conclusion from the high-impact JAMA Oncology landmark paper.
During the long delayed process, the vast majority of retail investors who have been repeatedly recognized as backbone of the support to the company by Linda have suffered emotionally and monetarily due to in a significant part, heavy dilution.
The management, mainly Linda and Les can and should show that we, the vast numbers of retail investors and the management are truly in the same boat; we shall suffer, endure, flourish and prosper together. The management can at least do the following:
1) Buy in open market, if having not yet scheduled, do now;
2) Rearrange the pay package. Cut substantially the future milestone payments of both shares and warrants; Compared to injecting new valor and confidence to the investment community by doing so, I don't see any difference of rewarding themselves with 30 millions or 15 millions of warrants (just example, not the real numbers); and
3) Throw off the shackles of the myth that FDA is a totally corrupted monster which has been better not poked or "offended" in any way so that NWBio shall continually operate in a stealthy mode behind the scene. Well the publication of the JAMA Oncology paper has changed that, or everything in effect. Nothing should we fear for now, and Linda and the gang shall embark on a new journey so that we won't be so passive anymore and instead we should take a more proactive role, fanning out people to promote the company as much as possible. Truth flourishes in light, not darkness!
When we remember the conclusion from the high impact JAMA Oncology paper re P3 DCVax-L trial for GBM: the results are "both statistically significant and clinically meaningful," nothing and nobody shall we fear! We should be in the teens when clouds are clear and dusts are settled. In the meanwhile, get dry powder ready to chase the shares until the 7 accused MMs and their complicit short can no longer manipulate the market.

Recent NWBO News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
- Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments • AllPennyStocks.com • 01/13/2025 01:56:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/26/2024 10:07:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:29:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:10:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
HealthLynked Welcomes Anthony Scuilla as Sales Consultant to Drive Strategic Partnerships with Insurance Providers • HLYK • Apr 14, 2025 8:00 AM
Glidelogic Corp. Partners with Sunwah Global Youth Innovation Center • GDLG • Apr 10, 2025 4:00 PM
Opus Holdings, Inc. (OTC: CATV) Reports Nearly $500K in Q4 Revenue, eliminates $830K in Debt, and Appoints Visionary CEO to Lead Bold Transformation • CATV • Apr 10, 2025 9:34 AM
AI-Powered Service Robots Redefine Hospitality as Industry Innovators Lead the Charge • NGTF • Apr 10, 2025 9:00 AM
UAV Corp Powers Forward: T-Wing Nears Completion, Global Momentum Accelerates with Saudi Arabia in Sight • UMAV • Apr 10, 2025 8:30 AM
UAV Corp and Genetic Networks Announce Strategic Collaboration to Combat Biohazards with Cutting-Edge Technology, Genetic Networks Signs MOU with UMAV • FITY • Apr 9, 2025 9:00 AM